FP7Individual fellowship2011–2013

GLIO_IL-23 · EFFECT OF IL-23 ON IMMUNE CELL INFILTRATION AND TUMOR GROWTH IN A GLIOMA MODEL

FP7 — People (Marie Curie Actions)

Duration
2011-03-01 → 2013-02-28
EU contribution
€179,102
Participants
1
Scheme
MC-IEF

Lines connect the coordinator with its partners.

Results in brief

EFFECT OF IL-23 ON IMMUNE CELL INFILTRATION AND TUMOR GROWTH IN A GLIOMA MODEL

Several hallmarks are involved in the development of cancer. As an example, induction of angiogenesis and evasion of the immune response are, amongst others, critical processes in the promotion of tumor cell survival and tumor growth. Thus, it has been described how glioblastoma cells display efficient mechanisms to avoid the host’s immune response. Malignant gliomas are considered one of the most aggressive cancers and the most common tumor affecting the central nervous system in humans. As a result, multiple current lines of research are focus on the development of new drugs with potential therapeutic effect. As with other experimental approaches testing new drugs, this work often requires in-vivo experimental studies. These studies involve the follow up of an experimental model and the discrimination of the effect induced by the tested drug. Considering that, the aim of the present project was to adapt a Fluorescence Molecular Tomography (FMT) system together with the acquisition and reconstruction method. This adapted system is aimed to allow the optical non-invasive in-vivo imaging of the mouse brain. Thus, the adapted system has been used for the in-vivo follow-up of tumor growth and tumor-associated protease activity in a glioma murine model. Moreover, experimental treatments have been tested and their potential anti-tumor effects have been evaluated. Two different aspects have been essential in the development of the present project: the adaptation of the optical system to fulfill the needs of our application and the experimental model to be used (in this case, a murine experimental model of glioma). In summary, the adaptations in the system have consisted on: a) designing and building a special holder which allowed us to perform the required optical measurements of the murine head; b) the adaptation of the system so as to obtain multispectral measurements (several pairs of excitation laser and emission filters); c) improvements in the acquisition procedures to allow measurements in an efficient manner; d) improvements in the reconstruction method. With these adaptations we are now able to acquire multispectral measurements and to obtain 3D reconstructed images of the different fluorescent signals. Regarding the model, the GL261 cell line was used. This is a widely used glioma cell line, which is orthotopically injected to establish an experimental in-vivo model of glioma. Stable transfectant expressing a near-infrared fluorescent protein (Turbo635 or iRFP) were obtained by transfection followed by clone selection. FACs analysis was used to select the clones with higher expression, based on the levels of intensity. The selected clones were then tested in-vivo and tumor growth was validated ex-vivo. On the other hand, commercially available fluorescent probes were also used for the determination of tumor protease activity in the glioma model. Analysis of the doses and kinetics of the fluorescent probes were performed in-vivo. Finally, FMT has also been used in combination with Magnetic Resonance Imaging (MRI). MRI has been used to validate 3D fluorescent images obtained by FMT. This system has successfully allowed us the in-vivo follow-up of tumor growth and tumor-associated protease activity in a glioma model. Moreover, potential beneficial effect of different treatments has been analyzed using this methodology. Results obtained in this regard are expected to be published soon in a high impact journal.

Data: CORDIS, © European Union

Project objective

Malignant gliomas are the most common primary central nervous system (CNS) tumors in humans and belong to the most aggressive types of cancer. Glioblastoma cells display an invasive phenotype and release immunosuppressive molecules to avoid the host’s immune response. Therefore, there is an urgent need for novel tumor-selective treatments that specifically target migratory glioma cells and/or promote inflammatory anti-tumor responses.The possibility of using immuno-therapy to control tumor growth is currently being investigated. Considering the CNS, this approach acquires unique characteristics due mainly to the existence of the blood brain barrier. In this regard, the IL-12/IL-23 superfamily of cytokines represents a promising immuno-therapy tool. Despite their structural similarities, they play different roles in the immune response promoting Th1 or Th17 polarization, respectively. Moreover, IL-23 but not IL-12 has been described as essential for the infiltration of CD4+ cells into the CNS in experimental autoimmune encephalomyelitis (EAE). Considering tumor growth, the anti-tumoral effects of IL-12 have been described in several models including glioma. However, in the case of IL-23 both tumor-promoting and tumor-suppressive effects have been reported, depending if endogenous or exogenous IL-23 is examined. Regarding glioma models, no data is available on how endogenous IL-23 may modulate tumor growth.The goal of this project is to evaluate the differences of endogenous and exogenous IL-23 effect on a glioma model. Moreover, the possible modulation exerted by IL-23 on immune cell infiltration into the CNS in a glioma context will be studied. To achieve these objectives, novel multimodal non-invasive molecular imaging techniques will be used, providing not only spatio-temporal information but also quantitative data regarding tumor growth, matrix-metalloproteinase activity and immune cell infiltration into the CNS.""

Original text from CORDIS.

Participants

  • EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH · ZuerichCoordinatorSwitzerland

Links

Data: CORDIS, © European Union